1. Home
  2. XBP vs TCRX Comparison

XBP vs TCRX Comparison

Compare XBP & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBP Europe Holdings Inc.

XBP

XBP Europe Holdings Inc.

N/A

Current Price

$2.89

Market Cap

41.3M

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.19

Market Cap

49.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBP
TCRX
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.3M
49.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
XBP
TCRX
Price
$2.89
$0.19
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
5.0K
★ 573.2K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 183.67
12.28
EPS
N/A
★ N/A
Revenue
★ $872,690,000.00
$10,325,000.00
Revenue This Year
$2.47
N/A
Revenue Next Year
$10.86
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 266.65
52 Week Low
$0.41
$0.18
52 Week High
$8.55
$1.97

Technical Indicators

Market Signals
Indicator
XBP
TCRX
Relative Strength Index (RSI) 46.62 28.41
Support Level $2.76 N/A
Resistance Level $3.00 $0.37
Average True Range (ATR) 0.18 0.02
MACD -0.02 0.01
Stochastic Oscillator 46.64 20.75

Price Performance

Historical Comparison
XBP
TCRX

About XBP XBP Europe Holdings Inc.

XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: